First AD

Second AD

 fusion+ metastatic non–ؘsmall-cell lung cancer and insights on approaching testing for 

Data from the following clinical trials are discussed:

Selpercatinib (LOXO-292) in patients with 

-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

Intracranial activity of selpercatinib (LOXO-292) in 

 fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced 

 fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

RET Fusion+ mNSCLC

Data from the following clinical trials are discussed:

Selpercatinib (LOXO-292) in patients with RET-fusion+ non–small cell lung cancer. (Goto K et al. 2020 ASCO annual meeting. Abstract 3584.)

Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non–small cell lung cancer patients on the LIBRETTO-001 trial. (Subbiah V et al. 2020 ASCO annual meeting. Abstract 9516.)

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients with advanced RET fusion+ non–small cell lung cancer. (Gainor JF et al. 2020 ASCO annual meeting. Abstract 9515.)